Triple Negative Breast Cancer News and Research

RSS

A single number aids biomedical data scientists in finding deadly cancer cells

Biomedical data scientists at the Stanford University School of Medicine have shown that the number of genes a cell uses to make RNA is a reliable indicator of how developed the cell is, a finding that could make it easier to target cancer-causing genes.

24 Jan 2020

UC Riverside research team receives NIH grant to study breast cancer

A research team led by biochemists at the University of California, Riverside, has received a four-year grant from the National Institutes of Health, or NIH, to study breast cancer -- the most common cancer in women worldwide -- and the racial disparities in the treatment of the disease.

8 Jan 2020

Can FDA-approved flu shots be repurposed as treatments for cancer?

Changing the microenvironment of tumors to increase the immune system's response to them has been the goal of countless research and clinical studies including the most recent use of checkpoint inhibitory antibodies.

7 Jan 2020

Phase II case-control trial initiated for four types of terminal cancers

The Alexandrov National Cancer Centre begins phase II case-control clinical trial of its immuno-oncology agent, Elenagen.

7 Jan 2020

Study reveals new role for a triple-negative breast cancer target

Unlike almost every other organ, the mammary gland does not develop until after birth. And it's unusually dynamic, shape-shifting during menstrual cycles, puberty, pregnancy, and lactation.

19 Dec 2019

IU researchers discover how to predict recurrence of triple negative breast cancer

Indiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and which women are likely to remain disease-free.

13 Dec 2019

New drug combo promises help for triple negative breast cancer patients

A new preclinical study on triple negative breast cancer (TNBC) reports that an experimental polo-like kinase 1 (PLK1) inhibitor shrank tumor four times more powerfully when used along with standard drugs than alone. The study, reported in the journal PLOS ONE, opens up a new door of opportunity for patients with this disease.

11 Dec 2019

Combination regimen shows promising results in preclinical models of triple negative breast cancer

Tumor volume in a preclinical model of triple negative breast cancer (TNBC) was reduced four times more when an experimental polo-like kinase 1 (PLK1) inhibitor was combined with a standard-of-care chemotherapeutic agent than when the agent was used alone.

10 Dec 2019

Innovative experimental therapy may stop growth of triple-negative breast cancer

Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.

9 Dec 2019

Researchers identify a missed opportunity in the treatment of ER+ breast cancers

In the United States, apart from some forms of skin cancer, breast cancer is the most common cancer in women. It is also the most common cause of death from cancer among Hispanic women and the second most common among all other women, after lung cancer.

6 Dec 2019

Researchers confirm two new prognostic markers for triple negative breast cancer

Physicians who treat patients with triple negative breast cancer have two new ways to predict which patients may benefit most from the well-established post-surgery treatment known as AC chemotherapy, short for adjuvant doxorubicin and cyclophosphamide.

5 Dec 2019

Researchers identify key protein required for therapeutic resistance in aggressive breast cancer

Researchers at the Lady Davis Institute have identified a key protein that is required for resistance to chemotherapy in the most aggressive form of breast cancer. This holds the promise of opening the door to new therapies for overcoming drug resistance.

2 Dec 2019

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

25 Nov 2019

Rutgers Cancer Institute researchers awarded $2.3 million in American Cancer Society grants

More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.

19 Nov 2019

Research breakthrough may lead to new therapeutic targets for cancers

Computational modeling is the use of computers to simulate and study the behavior of complex systems. Computational approaches are widely adopted in the bioimedical sciences and can be used to sift through large volumes of complex data to extract recurrent patterns that may point to a disease's causes and effects.

15 Nov 2019

Promising method to identify aggressive breast cancers that will respond to immunotherapy

University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer.

14 Nov 2019

Fresh light on why aggressive breast tumors form and how they can be treated

New research presented at the Society for Endocrinology annual conference in Brighton appears to identify novel methods of therapy for an aggressive type of breast cancer as well as uncovering potential causative factors. The focus of the study is to show how common chemicals present in our surroundings are possibly putting women at risk of a type of breast cancer called triple negative breast cancer (TNBC).

12 Nov 2019

New method for identifying 'biomarkers' of drug response in triple-negative breast cancer cell lines

Triple-negative breast cancer is an aggressive cancer, one that's likely to recur and to metastasize.

10 Nov 2019

Genetically definable subgroups of cancers sensitive to treatment

Precision oncology aims to use genetic features of a patient's tumor to tailor anti-cancer therapy. DNA mutations in a drug target have provided a number of therapeutic opportunities; however, there are many cancer types that do not have obvious targetable mutations.

24 Oct 2019

Dual action of genes and RNA influences aggressive triple-negative breast cancer

Women with an aggressive, less-common type of breast cancer, known as triple-negative, versus a more common form of the disease, could be differentiated from each other by a panel of 17 small RNA molecules that are directly influenced by genetic alterations typically found in cancer cells.

22 Oct 2019